These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12907538)

  • 1. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
    Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
    Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
    Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
    Lloyd A; Holman A; Evers T
    Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
    Lode H; Grossman C; Choudhri S; Haverstock D; McGivern J; Herman-Gnjidic Z; Church D
    Respir Med; 2003 Oct; 97(10):1134-42. PubMed ID: 14561021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H; Song X; Crespi S; Navaratnam P
    Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
    Lamping DL; Schroter S; Marquis P; Marrel A; Duprat-Lomon I; Sagnier PP
    Chest; 2002 Sep; 122(3):920-9. PubMed ID: 12226033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
    Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
    Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
    Hoeffken G; Talan D; Larsen LS; Peloquin S; Choudhri SH; Haverstock D; Jackson P; Church D
    Eur J Clin Microbiol Infect Dis; 2004 Oct; 23(10):772-5. PubMed ID: 15605184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
    Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
    Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
    Dresser LD; Niederman MS; Paladino JA
    Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
    Hoeffken G; Meyer HP; Winter J; Verhoef L;
    Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
    Torres A; Muir JF; Corris P; Kubin R; Duprat-Lomon I; Sagnier PP; Höffken G
    Eur Respir J; 2003 Jan; 21(1):135-43. PubMed ID: 12570122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
    Petitpretz P; Arvis P; Marel M; Moita J; Urueta J;
    Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
    Schaberg T; Ballin I; Huchon G; Bassaris H; Hampel B; Reimnitz P;
    J Int Med Res; 2001; 29(4):314-28. PubMed ID: 11675905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.
    Garau J; Fritsch A; Arvis P; Read RC
    J Chemother; 2010 Aug; 22(4):264-6. PubMed ID: 20685631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Gyssens IC; Dryden M; Kujath P; Nathwani D; Schaper N; Hampel B; Reimnitz P; Alder J; Arvis P
    J Antimicrob Chemother; 2011 Nov; 66(11):2632-42. PubMed ID: 21896561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.